{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:05:52Z","timestamp":1760123152397,"version":"3.37.3"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","onlinecjc.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.cjca.2022.02.018","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T16:10:13Z","timestamp":1645891813000},"page":"654-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1639-6359","authenticated-orcid":false,"given":"Graham R.","family":"McClure","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Kaplovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia S.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2022.02.018_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2022.02.018_bib2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2022.02.018_bib3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.113.000618","article-title":"Socioeconomic inequality and peripheral artery disease prevalence in US adults","volume":"7","author":"Pande","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjca.2022.02.018_bib4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2022.02.018_bib5","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jacc.2018.08.002","article-title":"Pathology of peripheral artery disease in patients with critical limb ischemia","volume":"72","author":"Narula","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.018_bib6","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.018_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11886-021-01472-9","article-title":"Prevention and management of urgent\/emergent limb ischemia","volume":"23","author":"McClure","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cjca.2022.02.018_bib8","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/1526602819866191","article-title":"A\u00a0new preprocedural score to predict bleeding complications of endovascular interventions for peripheral artery disease","volume":"26","author":"Spiliopoulos","year":"2019","journal-title":"J\u00a0Endovasc Ther"},{"issue":"9901","key":"10.1016\/j.cjca.2022.02.018_bib9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.02.018_bib10","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"7329","key":"10.1016\/j.cjca.2022.02.018_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"9038","key":"10.1016\/j.cjca.2022.02.018_bib12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.02.018_bib13","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2022.02.018_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.018_bib15","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1522-9","key":"10.1016\/j.cjca.2022.02.018_bib16","first-page":"1529e1","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2\u00b0P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.02.018_bib17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ahj.2014.06.017","article-title":"Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)","volume":"168","author":"Jones","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2022.02.018_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10117","key":"10.1016\/j.cjca.2022.02.018_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.02.018_bib20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/eurheartj\/ehx658","article-title":"External applicability of the COMPASS trial: an analysis of the Reduction of Atherothrombosis for Continued Health (REACH) registry","volume":"39","author":"Darmon","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2022.02.018_bib21","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","article-title":"Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial","volume":"73","author":"Anand","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.018_bib22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacc.2019.11.050","article-title":"Long-term outcomes and associations with major adverse limb events after peripheral artery revascularization","volume":"75","author":"Hess","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.018_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/M17-1058","article-title":"Readmissions after revascularization procedures for peripheral arterial disease: a nationwide cohort study","volume":"168","author":"Secemsky","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2022.02.018_bib24","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMoa2005206","article-title":"Mortality with paclitaxel-coated devices in peripheral artery disease","volume":"383","author":"Nordanstig","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.018_bib25","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy\u2014the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1016\/j.cjca.2022.02.018_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41431-019-0480-8","article-title":"Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe","volume":"28","author":"Petrovi\u0107","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.cjca.2022.02.018_bib27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/JCMA.0000000000000168","article-title":"CYP2C19 loss-of-function alleles: a common but overlooked problem associated with clopidogrel resistance","volume":"82","author":"Chi","year":"2019","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.cjca.2022.02.018_bib28","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/CIRCULATIONAHA.120.050465","article-title":"Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety","volume":"142","author":"Hiatt","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.02.018_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jvs.2014.03.244","article-title":"Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population","volume":"60","author":"Baril","year":"2014","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.cjca.2022.02.018_bib30","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial","volume":"71","author":"Anand","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.018_bib31","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.115.019355","volume":"133","author":"Bonaca","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.02.018_bib32","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cjca.2020.06.008","article-title":"A\u00a0national Canadian survey of antithrombotic therapy following urgent and emergent limb revascularization","volume":"37","author":"McClure","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2022.02.018_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2005.03.021","article-title":"The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials","volume":"151","year":"2006","journal-title":"Am Heart J"},{"issue":"9201","key":"10.1016\/j.cjca.2022.02.018_bib34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial","volume":"355","year":"2000","journal-title":"The Lancet"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X22001453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X22001453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T13:33:39Z","timestamp":1725716019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X22001453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0828282X22001453"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2022.02.018","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2022.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}